Werewolf Therapeutics reports Q4 2022 net loss $11.9M; cash runway extended through Q4 2024

Werewolf Therapeutics, Inc.

Net loss $11.9M for Q4 2022, compared to $17.9M in Q4 2021; full year net loss $53.8M (2021: $50.0M).
Cash and equivalents $129.3M at Dec 31, 2022; company drew down full $40M term loan, extending runway through at least Q4 2024.
Collaboration revenue $7.3M (Q4 2022) from Jazz licensing agreement; zero in prior year period.
Phase 1/1b WTX-124 (IL-2) dose-escalation ongoing; interim data expected in Q4 2023.
First patient dosed in Phase 1 WTX-330 (IL-12) trial in Feb 2023; WTX-712 (IL-21) nominated for preclinical development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (raised).

Period: the fourth quarter and full year ended December 31, 2022
Guidance: raised
Result: reported results

Exact text from the filing

On March 23, 2023, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.